NUZ -- New Investor thread, page-20

"Today’s TGA decision to not register LEQEMBI for AD underscores just how difficult it is to take ND drugs through to approval and what a unicorn we’re riding here with NUZ-001."

Thanks Densy,

Very interesting decision.

It would be great to be a "fly on the wall" at the pharma partnering conferences that Paul Field attended in Japan last week and the one Michael Thurn is attending in Houston this week.

I imagine there are quite a few companies looking for a unicorn with no side effects that provides efficacy in all neurodegenerative diseases.

In fact, at the AGM, Michael said some of the pharmaceutical companies talking to Paul in Japan had also requested meetings with him in Houston.

I can't wait to hear how NUZ-001 has performed against AD, PD and HD in these other pre-clinical trials.

Very exciting times on the Horizon.

Regards,

Havelots